Allovir Inc expected to post a loss of 42 cents a share - Earnings Preview

Kalaris Therapeutics

30/10/2023 18:04

* Allovir Inc  ALVR.OQ   ALVR.O  is expected to show no
change in
quarterly revenue when it reports  results 
    * 
    * ​Refinitiv's mean analyst estimate for Allovir Inc is for
a loss
of 42 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Allovir Inc
is
$18.5​, above​ its last closing price of $1.34. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.43       -0.45      -0.48     Missed  -6.7
 Mar. 31 2023  -0.46       -0.46      -0.44     Beat    5.4
 Dec. 31 2022  -0.56       -0.54      -0.37     Beat    31.9​
 Sep. 30 2022  -0.52       -0.53      -0.50     Beat    5.1
 ​​Jun.        -0.73       -0.73      -0.69     Beat    5.5
 30 2022                                                
 Mar. 31 2022  -0.80       -0.80      -0.69     Beat    13.4​
 Dec. 31 2021  -0.78       -0.81      -0.92     Missed  -13.1
 Sep. 30 2021  -0.58       -0.55      -0.72     Missed  -30.9
 This summary was machine generated October 30 at 18:04 GMT.  All
figures in US dollars  unless otherwise stated